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Abstract: Leveraging the immune system to thwart cancer is not a novel strategy and has been
explored via cancer vaccines and use of immunomodulators like interferons. However, it was
not until the introduction of immune checkpoint inhibitors that we realized the true potential of
immunotherapy in combating cancer. Oncolytic viruses are one such immunotherapeutic tool that
is currently being explored in cancer therapeutics. We present the most comprehensive systematic
review of all oncolytic viruses in Phase 1, 2, and 3 clinical trials published to date. We performed a
systematic review of all published clinical trials indexed in PubMed that utilized oncolytic viruses.
Trials were reviewed for type of oncolytic virus used, method of administration, study design, disease
type, primary outcome, and relevant adverse effects. A total of 120 trials were found; 86 trials
were available for our review. Included were 60 phase I trials, five phase I/II combination trials,
19 phase II trials, and two phase III clinical trials. Oncolytic viruses are feverously being evaluated
in oncology with over 30 different types of oncolytic viruses being explored either as a single agent
or in combination with other antitumor agents. To date, only one oncolytic virus therapy has
received an FDA approval but advances in bioengineering techniques and our understanding of
immunomodulation to heighten oncolytic virus replication and improve tumor kill raises optimism
for its future drug development.
Keywords: immunotherapy; clinical trials; oncolytic viruses
1. Introduction
Enhancing the body’s own response to malignant cells through immune stimulation has been a
vigorous focus of recent cancer research. Oncolytic viruses (OVs) are one such tool. These viruses are
naturally occurring or can be modified to selectively infect and destroy cancer cells. In addition, there is
evidence OVs can stimulate the host’s immune response to combat tumors [1]. Multiple viruses are
currently under investigation including herpesvirus, adenovirus, poxvirus, picornavirus, and reovirus
as possible oncolytic treatments. In 2015 talimogene herparepvec was the first OV approved by the
Food and Drug Administration (FDA) for human use in the USA [2] and there are a number of other
OVs currently in phase III testing. Here we discuss how OVs have been adapted to destroy cancer cells
and summarize the clinical data on OVs currently under investigation.
2. Methods
In our systematic review we collected all published clinical trials that utilized oncolytic viruses.
Using Pubmed, we first narrowed our search to include “Clinical Trials” and “Humans.” Subsequent
Int. J. Mol. Sci. 2020, 21, 7505; doi:10.3390/ijms21207505 www.mdpi.com/journal/ijms
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search criteria included “oncolytic virus”, “oncolytic virotherapy”, “oncolytic immunotherapy”,
and “oncolytic vaccine”. Our initial search returned 120 articles. This preliminary search also captured
reviews, proposed study protocols, and opinion pieces, which were excluded (26 in total). Papers
not available in full text for review, or with no available English translation were excluded (4).
Last, we found a limited number of articles that described different facets of the same trial, and these
redundant articles were excluded (4). One unpublished study was identified in clinicaltrials.gov.
In summary, we used 86 total trials, including 60 phase I, 5 phase I/II, 19 phase II, and 2 phase III trials
for our review. See Figure 1 for a schematic representation of systematic review of OV clinical trial
data and exclusion criteria.
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3. Mechanism of Action
OV therapy relies on a two-part process of selectively infecting tumor cells, and then inducing
antitumor activity through release of tumor antigens and immune stimulation (Figure 2).
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4. Targeting Cancer Cells
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nectins and herpes virus entry m di tor (HVEM), expressed on cancer cell m mbranes, to gain entry.
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Other OV’s are nhanced viruses that have be n tailored o in rease their affinity for malignant
tissues. They are engi eered to targ t pro eins ov rexpress in cancer cells. One such example is
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thymidine kinase (TK). A strain of HSV has been modified to favor tumor cells due to their high TK
expression [7]. TK is an enzyme used for DNA synthesis and repair during cell replication, is therefore
highly expressed on tumor cells. This engineered variant of HSV holds a TK-knock out. The knockout
of TK results in preferential infection and destruction of cancerous tissues.
5. Direct Tumor Cell Lysis
After target infection of the tumor cell occurs, lysis of the tumor cell leads to the release of
viral particles, cytokines, and other cellular contents, and a secondary response to this lysis ensues.
Within this system, there is direct killing of surrounding cells by the release of these cytotoxic elements,
which include granzymes and perforins. The cellular contents ATP, uric acid, and heat shock protein
are known as danger-associated molecular patterns (DAMPs), which cause local inflammation. DAMPs
and cytokines attract natural killer (NK) cells to the surrounding tissue. In addition, viral particles have
protein sequences that can stimulate the immune system, known as pathogen associated molecular
patterns (PAMPs).
OVs can also be engineered to deliver suicide genes to enhance direct tumor cell lysis. These genes
encode enzymes that can convert prodrug into an active form to destroy tumor cells. ProstAtak
(aglatimagene besadenovec) is an OV engineered to express HSV TK in infected cells; after injection,
valcyclovir is administered that halts DNA replication in the tumor cell.
6. Antitumor Activity
OV antitumor activity depends on both direct malignant cell destruction as well as a stimulating
systemic antitumor immunity. This immunity is induced when an infected cell is lysed. The viral
antigens and cellular components are liberated into the cancer microenvironment. Release of DAMPs,
PAMPs, and cytokines lead to maturation of antigen presenting cells (APCs), including the dendritic
cells (DC). By these processes, tumor cells that had previously evaded the immune system can now
be recognized and targeted by the immune system; destruction pattern recognition receptors (PRRs)
on immune cells are stimulated to recognize these PAMPs and DAMPs. PRRs specific to dendritic
cells (DC)s within tumors can be directly stimulated by OV infection [8]. The subsequent activation
of APCs then recruit CD4+ and CD8+ cells to destroy cells expressing viral antigens on tumors.
One such example, in the activation antiviral CD8 T cells by reovirus lead to tumor regression [9].
This recognition of tumor antigens by the immune system is key to tumor destruction at distant sites
that were not infected with the OV [10].
HSV and reovirus can prime antitumor immunity by stimulating T cell activity to destroy
neighboring tumor cells [11,12]. Another genetically modified variant of HSV, Talimogene herparepvec
(T-vec), has the GM-CSF cistron inserted into its genome. This modification enables high production
and release of GM-CSF when the tumor cells are destroyed, resulting in enhanced DC recruitment and
antigen presentation [13].
In addition to targeting the malignant cells themselves, OVs can destroy tumor vasculature.
Some OVs are engineered to target angiogenesis, and other viruses inherently target the destruction of
tumor vasculature. HSV and vaccinia viruses are one such example. These viruses depend on high
expression of fibroblast growth factor and vascular endothelial growth factor (VEGF) for replication to
target new tumor vessels [14,15]. The vesicular stomatitis virus (VSV) has been shown to infect blood
vessels surrounding a tumor and cause thrombosis of its vessels [16].
7. Novel Trends in OV Advancements
Much of the emerging research for OVs focuses on how to amplify their immunogenicity and
tumor destruction through insertion or exchange of human genes. These genes can improve cancer cell
destruction through improved entry into cells, direct destruction of cancer cells, or recruitment of the
patient’s immune system. These emerging viruses are particularly focused on recruitment of the host’s
immune system to destroy the tumor.
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One such virus in an ongoing phase 1 clinical trial utilizes a strain of HSV-1 to target glioblastomas
(NCT02062827) [17]. This OV was modified to express IL-12, which improves the OV’s efficacy in
destroying tumor cells and in the surrounding microenvironment. The release of IL-12 with tumor
lysis leads to recruitment of dendritic cells, monocytes, and macrophages to the area for increased
tumor destruction. The release IL-12 also exhibits an anti-angiogenic effect, which slows the growth of
blood vessels for the tumor and decreases tumor growth.
TILT-123 is another exciting example of an OV equipped with proteins to enhance its anti-tumor
activity. TILT-123 is an adenovirus engineered to express TNF-alpha and IL2 (NCT04217473) [18].
While infection with the OV can lead to tumor destruction as previously discussed, the addition of IL2
and TNF-alpha increases the immunogenicity of the therapy. Expression of TNF-alpha and IL-2 attracts
T cells to the tumor and also enhances their infiltration into the cancer cells [19]. NCT04217473 is the
first clinical trial to evaluate the safety of TILT-123′s in patients with advanced melanoma, enrolling
patients in early 2020.
In addition to studies currently underway combining OVs with simultaneous checkpoint
inhibitor therapy administration, viruses are being engineered to produce the antibodies themselves.
An HSV-1 virus has recently been developed for use in glioblastoma therapy, which can express PD-1
antibodies [20]. While this construct has only been tested in murine models as of now, it is a promising
example of enhancing OV tumor activity through gene insertion.
8. Augmentation of Immune Checkpoint Inhibition. “Making Cold Tumors Hot: Immune
Checkpoint Inhibitor–OV Combination Therapy Trials”
Remarkable progress has been made in the development of immunotherapy to treat cancers
in the last decade. One type of immunotherapy is immune checkpoint inhibitors (ICBs), which are
monoclonal antibodies that block receptor-ligand interactions that negatively regulate both innate and
adaptive immunity. Prominent examples of ICBs include those that target cytotoxic T lymphocyte
antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) [21]. To date, multiple ICBs have been
approved by the FDA to treat cancers; for example, ipilimumab (blocks CTLA-4), nivolumab (blocks
PD-1), and pembrolizumab (blocks PD-1).
Combination therapies that use ICBs and oncolytic viruses are attractive. The oncolytic virus
can recruit tumor-infiltrating lymphocytes into immune-deficient tumors and trigger the release of
soluble tumor antigens, danger signals, and proinflammatory cytokines, which further increase T cell
recruitment and promote immune cell activation [10,22]. Viral infection also increases the expression of
CTLA-4, PD-1, and other immune checkpoint molecules, which would usually block T cell activation
(and therefore antitumor immunity) but also sensitizes tumors to ICBs [23,24]. Non-clinical studies
using B16–F10 melanoma demonstrated that localized injection of tumors with oncolytic Newcastle
disease virus induced infiltration of tumor-specific CD4+ T cells and CD8+ T cells into both the injected
tumor and distant tumors; this action increased the sensitivity of the tumors to systemic CTLA-4
blockade [10]. In another non-clinical model of triple-negative breast cancer, an oncolytic Maraba virus
had activity as a neoadjuvant therapeutic, and it sensitized otherwise refractory tumors to ICB [25].
Other oncolytic viruses, such as B18R-deficient vaccinia virus [26] and vesicular stomatitis virus,
express a library of melanoma antigens [27] and also showed significant (p < 0.05) therapeutic benefit
in combination with ICB.
There is a strong mechanistic rationale for using combination oncolytic virus and ICBs since
immune activation in the tumor environment as well as neo antigen production from oncolytic virus
can improve efficacy of ICBs.
Ribas et al. confirmed that OV can potentially improve efficacy of anti PD1 immune checkpoint
inhibitors. They evaluated safety and efficacy of combination T- VEC (talimogene laherparepvec) and
pembrolizumab in a Phase 1b melanoma clinical trial (n = 21) and confirmed 62% objective response
rate. The investigators found that OV can favorably alter tumor microenvironment (elevated CD8+ T
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cells, upregulation of INF-gamma, and increased expression of PD-L1 protein) resulted in improved
response to the immune checkpoint inhibitor [28].
Improved efficacy was shown in Phase 2 clinical trial of combination oncolytic virus and
CTLA-4 targeting ICBs [29]. Chesney et al. evaluated the combination T-VEC and Ipilimumab in
a randomized phase II melanoma study (N = 198). 39 % patients had objective responses in the
combination T-VEC/Ipilimumab arm while only 18% objective response was observed in the single
agent ipilimumab arm (95% CI, P = 0.002). Of note, the responses were seen in injected lesions but also
reported in distant visceral lesions in 52 % patients in the combination arm vs. only 23 % in the single
agent ipilimumab arm.
A novel oncolytic virus called Coxsackievirus A21 (CAVATAK) shows synergy when combined
with immune checkpoint inhibitors [30]. The CAVATAK virus makes entry to cancer cells via ICAM1,
which is often abundant on tumors. A clinical trial evaluating cavatak virus in combination with
ipilimumab showed 50% objective responses in melanoma patients. Similarly, a trial evaluating
combination cavatak virus with pembrolizumab in advance solid tumors reveled no dose limiting
toxicities (DLT) [31]. A phase 1b Keynote 200 clinical trial of combination cavatak + pembrolizumab
in advance non-small cell lung cancer and bladder cancer confirmed no DLT; 12.8% grade 3
treatment-related adverse events were noted, however no grade 4 or 5 toxicities were seen [32,33].
Table 1 summarizes combination immune checkpoint and oncolytic virus clinical trials.
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Table 1. Summary of combination oncolytic virus and immune checkpoint inhibitor (ici) clinical trials.
Trial Name Virus/ICI Cancer n Central Questions and/or Outcomes
Oncolytic Virotherapy Promotes Intratumoral T
Cell Infiltration and Improves Anti-PD-1
Immunotherapy [28] (Ribas 2017)
Talimogene Laherparepvec (T-VEC)
ICI: Pembrolizumab Melanoma 21
Safety and efficacy evaluation of combination
T-VEC+Pembrolizumab in melanoma.
No dose limiting toxicities noted. 62%
confirmed objective responses.
Randomized, Open-Label Phase II Study
Evaluating the Efficacy and Safety of Talimogene
Laherparepvec in Combination with Ipilimumab
Versus Ipilimumab Alone in Patients with
Advanced, Unresectable Melanoma [29]
(Chesney 2018)
Talimogene Laherparepvec (T-VEC)
ICI: Ipilimumab Melanoma 198
Efficacy evaluation of combination
Ipilimumab+T-VEC vs. Ipilimumab alone in
advance melanoma. 39% Objective response
rate (ORR) in combination T-VEC/Ipilimumab
arm vs. 18% ORR in single agent Ipilimumab
arm. 52% pts showed reduction in visceral
lesions in combination arm as compared to
only 23% pts in single agent ipilimumab arm.
Objective Response Rate Among Patients with
Locally Advanced or Metastatic Sarcoma Treated
with Talimogene Laherparepvec in Combination
with Pembrolizumab [34] (Kelly 2020)
Talimogene Laherparepvec (T-VEC)
ICI: Pembrolizumab Sarcoma 20
Phase II study evaluating efficaciy of
combination T-VEC and pembrolizumab in
metastatic sarcoma. 35% best objective
response rate. 20% grade 3 AE and no grade 4
AE noted.
LBA40-Phase Ib KEYNOTE-200: A study of an
intravenously delivered oncolytic virus,
coxsackievirus A21 in combination with
pembrolizumab in advanced NSCLC and
bladder cancer patients [32] (Rudin 2018)
Cavatak (Coxsackievirus A21)
ICI: Pembrolizumab NSCLC; Bladder Cancer 78
No DLT noted. 12% pts reported to have grade
3 treatment related adverse events. No grade 4
or 5 toxicities reported.
AE, adverse response; DLT, dose limiting toxicity; ORR, objective response rate; NSCLC non-small cell lung cancer; PD-1, programmed cell death protein 1.
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9. Modes of OV Delivery
Depending on both the OV and cancer, virus administration can be delivered using a systemic or
more targeted approach.
9.1. Intralesional Route
A locoregional approach has been used for melanoma, prostate, and gliomas. Intradermal injections
of T-vec is employed for melanoma, intracavitary injection for gliomas, and intraperitoneal injection
for treatment of ovarian cancer are a few examples. Depending on the location and accessibility of the
tumors the virus can be delivered once (i.e., to a glioma cavity during surgery) or rely on repeated
injections such as in melanoma [35]. The efficacy of intratumoral injection can extend beyond the
lesions injected. Studies report evidence of tumor lysis in satellite lesions not injected with virus [36].
OV delivery can also employ intravenous (IV) release, through either peripheral IV injection, or more
targeted, through hepatic artery infusion for liver metastasis [37].
Intralesional injection can be limited by the extracellular matrix that surrounds otherwise accessible
tumors. In desmoplastic tissues, the spread of the virus can be limited by excessive fibrin and connective
tissues [38]. Agents such as bacterial collagenase have been used to increase the spread OV injection for
local tumors such as melanoma, which demonstrated some efficacy [39]. However, collagenase cannot
be used systemically, which limits its application. One of many systemic agents under investigation
includes the antihypertensive agent losartan, which reportedly decreased collagen deposition, increased
blood flow as well as uptake of the cytotoxic agent in pancreatic cancer [40].
Vascular injection also has limitations. Tumor vasculature is markedly disorganized and more
unstable than normal vessels [41]; this property makes vascular injections less reliable for downstream
delivery of the virus to surrounding cancer cells. However, currently there are several avenues under
investigation to stabilize these tissues and enhance delivery of cancer immunotherapy; some examples
include the use of nitric oxide [42] and VEGF [43].
9.2. Intravenous Route
Intra lesional OV administration is currently by far the most commonly used delivery method.
However many trials are also evaluating intravenous route of administration [44,45] due to its inherent
advantages. Some of the advantages of IV route includes ease of administration, standardization of
administered drug dose, potential for multiple and long term administration, and wider application of
IV based treatment especially in smaller community clinics [46]. The key detriment to IV administration
so far has been development of neutralizing antibodies and clearance of OV [47–49]. There are at least
eight clinical studies that we can confirm which used IV route for OV administration.
10. Phase I Trials
In our systematic review we have summarized 59 phase I trials investigating 36 OVs. Phase I
trials seek to demonstrate safety and dosing. Of those 36 viruses, many did not proceed past this initial
phase of investigation, or were altered in some way to improve efficacy. It is not feasible to summarize
all Phase I trials here, but a summary of all reviewed trials can be found in Table 2 Here we discuss a
few OVs of interest, many of which show promise and have progressed to Phase II investigations.
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Table 2. Summary of oncolytic virus use in phase I clinical trials.
Trial Name Virus Cancer n Administration, Adverse Events, Study Conclusions
Potential for efficacy of the oncolytic Herpes
simplex virus 1716 in patients with oral squamous
cell carcinoma [50] (Mace 2008).
HSV1716 Oral squamous cell carcinoma 20
Study used intratumoral injection of HSV 1716; no reportable
AE, but no detectable viral replication or effective oncolysis.
Study of higher doses required.
Intratumoral injection of HSV1716, an oncolytic
herpes virus, is safe and shows evidence of
immune response and viral replication in young
cancer patients [51] (Streby 2017).
HSV1716 Pediatric extracranial cancers 9
Study used intratumoral injection of HSV1716; no major AE:
mild constitutional symptoms (fever, chills, cyotopenia)
reported. No clinical responses seen by RECIST criteria but
viral replication was detected, and signs of inflammatory
response was seen on PET/CT.
A phase I study of OncoVEXGM-CSF,
a second-generation oncolytic herpes simplex
virus expressing granulocyte macrophage
colony-stimulating factor [52] (Hu 2006).
OncoVEXGM–CSF (Herpes Virus
JS1/34·5-/47-/GM-CSF)
Breast, head and neck, GI,
melanoma 30
Study used intratumoral injection at different dose levels in
30 patients. AEs: fever, and injection site reaction.
Three patients with SD. Some evidence of tumor necrosis was
seen on biopsy which was strongly positive for HSV.
A phase 1 trial of oncolytic HSV-1, G207, given in
combination with radiation for recurrent GBM
demonstrates safety and radiographic responses
[53] (Markert 2014).
G207 (HSV-1) GBM 9
Intratumoral injection of G207 given 24 h prior to radiation.
67% with SD or PR. 3 patients with measurable response to
radiation. No HSV encephalitis occurred.
A herpes oncolytic virus can be delivered via the
vasculature to produce biologic changes in human
colorectal cancer [54] (Fong 2009).
NV1020
Metastatic colon cancer in
liver previously refractory to
chemotherapy (5 FU and
leucovorin)
12
Study used IV injection of NV1020 into the hepatic artery.
CEA levels dropped in patients, and one patient saw 75%
reduction of tumor volume. Study reports 7 with SD, 3 with PD,
2 patients with reduction in tumor size at 28 days. Subsequent
chemotherapy was hepatic artery injection of floxuridine with
dexamethasone. All patients had PR. Results confounded by
varying systemic chemotherapy regimens (7 had irinotecan,
2 with oxaliplatin and 3 got both).
Intradermal injection of Newcastle disease
virus-modified autologous melanoma cell lysate
and interleukin-2 for adjuvant treatment of
melanoma patients with resectable stage III disease
[55] (Voit 2003).
Newcastle disease virus
(modified with autologous
melanoma cell lysate and IL-2)
Melanoma 29 Double blind study with placebo or viral injection afterresection of melanoma. No clinical efficacy demonstrated.
Phase I trial of intravenous administration of
PV701, an oncolytic virus, in patients with
advanced solid cancers [56] (Pecora 2002).
PV701 (Newcastle virus) Advanced solid cancers 79
Patients with advanced solid cancers refractory to traditional
therapies were divided into 4 groups of differing dosing
schedules (single and multiple dosing schedules). Virus was
administered via IV. 62 patients were available for assessment
with 1 PR and 1 CR. AE included fever, chills,
nausea, hypotension.
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Table 2. Cont.
Trial Name Virus Cancer n Administration, Adverse Events, Study Conclusions
A phase 1 clinical study of intravenous
administration of PV701, an oncolytic virus, using
two-step desensitization [57] (Laurie 2006).
PV701 (Newcastle virus) Advanced solid tumors 16
Previous studies (citation) demonstrated that patients could
tolerate a much higher dose of the virus if they were
desensitized first, so this study executed a two-step
desensitization. Minimal constitutional symptoms reported,
that decreased with subsequent doses. Symptoms were also less
severe than in previous studies. Study reports, 1 tumor
regression, and 4 SD.
An optimized clinical regimen for the oncolytic
virus PV701 [58] (Hotte 2007). PV701 (Newcastle virus) Advanced cancers 18
Study used IV infusions of PV701 at a slow rate. Decreasing the
infusion rate allowed patients to receive higher doses of the
virus, with fewer AE (particularly decreased constitutional
symptoms) and minimized infusion site reaction. Study reports
1 CR, 3 PR, 2 with minor response, and 5 with SD.
Phase I trial of cyclophosphamide as an immune
modulator for optimizing oncolytic reovirus
delivery to solid tumors [59] (Roulstone 2015).
RT3D (Reovirus Type 3 Dearing) Advanced solid tumors 36
Study used combination cyclophosphamide and RT3D
(intravenously) to decrease neutralizing antibodies to the virus.
While it was well tolerated, it did not reduce NARA
(neutralizing antireovirus antibody) titer.
A phase I study of the combination of intravenous
reovirus type 3 Dearing and gemcitabine in
patients with advanced cancer [60] (Lolkema 2011).
RT3D (Reovirus Type 3 Dearing) advanced solid cancers 16
First study to combine IV Reovirus with chemotherapy.
AE were similar to previous studies with fever,
nausea/vomiting, and chills. Protocol revised because there
were grade 3 rises in LFTs (but these patients were also taking
acetaminophen.) Reovirus may exacerbate gemcitabine-related
liver toxicity. Clinical response was best in a patient with
nasopharyngeal cancer, but OR minimal.
A phase I study of intravenous oncolytic reovirus
type 3 Dearing in patients with advanced
cancer [61] (Vidal 2008).
RT3D (Reovirus Type 3 Dearing) Advanced cancers 36
Patients received escalating doses of IV Reovirus. There were
no dose limiting toxicities, but some grade 1–2 flu-like
symptoms were reported and were dose dependent.
Some antitumor activity was observed by monitoring serum
tumor marker levels, but not by RECIST criteria. Neutralizing
Ab were detected in all patients
A phase I trial of intratumoral administration of
reovirus in patients with histologically confirmed
recurrent malignant gliomas [62] (Forsyth 2008).
Reolysin Recurrent malignant gliomas 12
Study used intratumoral injection of reovirus with escalating
doses. No grade 3–4 adverse events. Study reported 1 SD,
10 with PD. (1 was unable to be evaluated)
Two-stage phase I dose-escalation study of
intratumoral reovirus type 3 dearing and palliative
radiotherapy in patients with advanced
cancers [63] (Harrington 2010)
Reolysin Advanced solid cancers opento palliative radiation 23
Protocol used escalating doses of radiotherapy followed by
intratumoral injections of RT3D. AE included flu-like
symptoms (grade 2 or less) as well as neutropenia and
lymphopenia. Low dose group had 2 with PR and 5 with SD,
and in the high dose group 5/7 had PR and 2/7 with SD.
No viral shedding seen in bodily fluids.
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Table 2. Cont.
Trial Name Virus Cancer n Administration, Adverse Events, Study Conclusions
REO-10: a phase I study of intravenous reovirus
and docetaxel in patients with advanced
cancer [64] (Comins 2010).
Reolysin Advanced solid cancers 16
Study used IV Reolysin in combination with docetaxel
chemotherapy. There was 1 CR, 3 PR, and 10 with SD.
Overall 88% of patients had some degree of disease control.
One grade 4 neutropenia was reported.
REO-001: A phase I trial of percutaneous
intralesional administration of reovirus type 3
dearing (Reolysin®) in patients with advanced
solid tumors [65] (Morris 2013).
Reolysin Advanced solid tumors 19
Study used intra-lesional injection of virus and was well
tolerated. Most reactions were grade 1–2, including malaise,
and some erythema around injection site. Study reported 37%
with local tumor response, including 1 CR, 3 PR, and 4 with SD.
A phase I trial of single-agent reolysin in patients
with relapsed multiple myeloma [66] (Sborov 2014) Reolysin Multiple myeloma 12
Virus administered intravenously. No dose limiting AE
reported but grade 3 AE included hypophosphatemia,
thrombocytopenia, and neutropenia. While the virus did
replicate in MM cells, there was little viral protein recovered
from cells. Researchers concluded it could work as part of a
combination therapy, but not as monotherapy.
Phase 1 clinical trial of intratumoral reovirus
infusion for the treatment of recurrent malignant
gliomas in adults [67] (Kicielinski 2014)
Reolysin Malignant glioma 15
Study used intratumoral injection. This was a dose finding
study (previous study established safety). No MTD or dose
limiting toxicity identified. Adverse effects related to
underlying cancer, such as seizure, convulsions rather than
virus. Study reported 1 PR, and a few with SD
A phase I trial and viral clearance study of reovirus
(Reolysin) in children with relapsed or refractory
extra-cranial solid tumors: a Children’s Oncology
Group Phase I Consortium report [68] (Kolb 2015).
Reolysin Extracranial solid tumors 24
Study used IV injection of Reolysin alone or with
cyclophosphamide. No objective response to therapy, and only
1/3 of patients had a detectable viral load after 5 days; none did
after 17 days. Study reports 1 grade 5 respiratory failure and
1 grade 5 thromboembolic event.
Recurrent glioblastoma treated with recombinant
poliovirus [69] (Desjardins 2018)
PVSRIPO
(Polio Virus) Glioblastoma 61
Virus was injected intratumorally. Grade 4 ICH at the highest
injection dose was the only dose-limiting toxicity. Survival rate
was higher in those who received therapy as compared to
historical controls, at both 24 and 36 months.
Immunological effects of low-dose
cyclophosphamide in cancer patients treated with
oncolytic adenovirus [70] (Cerullo 2011).
Ad5/3-(delta)24 Advanced solid tumorsresistant to chemotherapy 21
Study used intratumoral injection with adenovirus followed by
cyclophosphamide treatment in different dosing groups.
AE were mostly grade 1–2 constitutional symptoms. The one
year PFS and OS was increased compared to traditional
chemotherapy resistant cancers. Study reports 8/12 patients
with RECIST response: 2 with MR, 6 with SD, and 4 with PD.
A phase I clinical trial of Ad5/3-∆24, a novel
serotype-chimeric, infectivity-enhanced,
conditionally-replicative adenovirus (CRAd), in
patients with recurrent ovarian cancer [71]
(Kim 2013).
Ad5/3-(delta)24 Ovarian Cancer 9
Study used intraperitoneal injection of the virus. AE were
flu-like grade 1–2: fever/chills, myalgias, fatigue, and nausea.
Study reported 3 patients with a decrease in CA-125 levels
at 1 month.
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A phase I study of a tropism-modified
conditionally replicative adenovirus for recurrent
malignant gynecologic diseases [72]
(Kimball 2010).
Ad5/3-(delta)24 Gynecologic malignancy 21
Study used intraperitoneal injection of virus. Reported grade
1-2 adverse events included fatigue, fever an abdominal pain.
Study reported 71% of patients had SD, and the remainder had
PD at 1 month. No CR or PR were achieved.
Integrin targeted oncolytic adenoviruses
Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for
treatment of patients with advanced chemotherapy
refractory solid tumors [73] (Pesonen 2012).
Ad5-D24-RGD and
Ad5-RGD-D24-GMCSF
advanced solid tumors
resistant to chemotherapy 16
16 patients were injected with adenovirus, 9 treated with
Ad5-D24-RGD, and 7 treated with Ad5-RGD-D24-GMCSF.
Virus for one group contained GM-CSF; as large tumors have
immunosuppressive characteristics, GM-CSF might stimulate
the immune system. Some patients in the GMCSF group
showed SD, while all patients in the other group progressed.
AE were low grade (1–2); constitutional symptoms or
injection site pain.
Antiviral and antitumor T cell immunity in
patients treated with GM-CSF-coding oncolytic
adenovirus [74] (Kanerva 2013).
CGTG-102
(Ad5/3-delta24-GMCSF) Advanced solid tumors 60
60 patients received intratumoral injections. The study
compared single injection (39 patients) to multiple injections
(21 patients) to establish safety of multiple. Stable disease or
better was achieved in 50% with serial injection vs. 41% with
single injection. Mostly grade 1–2 AE occurred
(constitutional symptoms).
Immunological data from cancer patients treated
with Ad5/3-E2F-∆24-GMCSF suggests utility for
tumor immunotherapy [75] (Hemminki 2015).
CGTG-602
(Ad5/3-E2F-delta24-GMCSF) Advanced solid tumors 13
13 patients enrolled with varying doses and treatment rounds
of virus via IV. 50% of patients noted a response to treatment.
AE were predominately grade 1–2 constitutional symptoms,
but some grade 3 AE were seen.
A phase I trial of CV706, a replication-competent,
PSA selective oncolytic adenovirus, for the
treatment of locally recurrent prostate cancer
following radiation therapy [76] (DeWeese 2001).
CV706 (PSA selective
adenovirus) Prostate cancer 20
Study used intraprostatic injection of virus into patients with
locally recurrent prostate cancer. There were no grade 3 or
greater toxicities. There was evidence of replication in biopsy
tissues. Those treated with higher doses of the virus had at least
50% drop in PSA levels.
A phase I trial of intravenous CG7870, a
replication-selective, prostate-specific
antigen-targeted oncolytic adenovirus, for the
treatment of hormone-refractory, metastatic
prostate cancer [77] (Small 2006).
CG7870 Hormone refractorymetastatic prostate cancer 23
Patients received intravenous dosing of the virus. Most AE
were constitutional symptoms such as fatigue, fevers, nausea.
Three grade 3 reactions occurred, including severe fatigue.
MTD was reached due to transaminitis and elevated d-dimer
levels. Using PSA as the endpoint, study reported 5 patients
with PSA reduction of 25–49% after 1 treatment, but no PR or
CR were reported.
A first in human phase 1 study of CG0070, a
GM-CSF expressing oncolytic adenovirus, for the
treatment of nonmuscle invasive bladder
cancer [78] (Burke 2012).
CG0070 (GM-CSF expressing
adenovirus) Bladder cancer (non-muscle) 35
Patients received intravesical infusions of virus. Grade 1–2
bladder toxicities were the most frequent AE but 3 patients had
grade 3 reactions for nocturia, dysuria and lymphopenia. Study
reported CR of 48.6% across all groups, and higher (58.3%) in
those with high Rb phosphorylation.
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A Phase I study of KH901, a conditionally
replicating granulocyte-macrophage
colony-stimulating factor: armed oncolytic
adenovirus for the treatment of head and neck
cancers [79] (Chang 2009).
KH901 (GM-GSF Expressing
Adenovirus)
recurrent head and neck
cancers 23
KH901, selective for cells expressing telomerase, was injected
intratumorally in patients with recurrent head and neck cancer.
Groups included single, and multi-dose injections at escalating
dosages. There were was no dose-limiting AE; majority were
grade 1-2 constitutional symptoms. Study reports 7/19 patients
with PD, 12 with SD.
Oncolytic adenovirus ICOVIR-7 in patients with
advanced and refractory solid tumors [80]
(Nokisalmi 2010).
ICOVIR-7 (adenovirus) Advanced solid tumors 21
Study used intratumoral injection at varying doses. One grade
3 anemia was observed, while remaining side effects were grade
1–2 and included flu-like symptoms, increased liver
transaminases, and hyponatremia. Study reported 5 objective
responses including 1 PR, 2 minor, and 2 SD. All patients had
PD prior to trial initiation.
A phase I trial of intratumoral administration of
recombinant oncolytic adenovirus overexpressing
HSP70 in advanced solid tumor patients [81]
(Li 2009).
Telomelysin/OBP-301
(adenovirus with human
telomerase reverse
transcriptase, hTERT)
Advanced solid tumors 27
Study used intratumoral injection of virus in a dose escalation
phase I study. Rare grade III fever and grave IV
thrombocytopenia at high doses were observed. Most AE were
fever, reaction at the injection site, as well as thrombocytopenia,
and depressed leukocyte and lymphocyte counts. Study
reported a minimum of 48% with SD, and 11% had CR or PR.
A phase I open-label, dose-escalation,
multi-institutional trial of injection with an
E1B-Attenuated adenovirus, ONYX-015, into the
peritumoral region of recurrent malignant gliomas,
in the adjuvant setting [82] (Chiocca 2004).
ONYX-015 Malignant glioma 24
24 patients received varying doses of ONYX-015 injected into 10
areas of the resected glioma cavity. No severe AE were reported
that were likely related to treatment (10 patient did have AE,
including 1 grade 3–4 neuropathy) Only 1 patient did not have
PD and No real treatment effect could be correlated with the
viral treatment.
A phase I trial of intravenous infusion of
ONYX-015 and Enbrel in solid tumor patients [83]
(Nemunaitis 2007).
ONYX-015 Advanced cancers 9
Nine patients divided in 3 groups received IV infusion of
onyx-015 of varying doses, with a dose of Enbrel.
Study reported 4/9 with SD, but no regression was seen.
AE were mild. Circulating viral DNA was higher when virus
infusion is given in combination with Enbrel
A phase I study of Onyx-015, an E1B attenuated
adenovirus, administered intratumorally to
patients with recurrent head and neck cancer [84]
(Ganly 2000).
ONYX-15 Recurrent head and neckcancer 22
Study used single intratumoral injection that was well tolerated.
Grade 1–2 constitutional symptoms were most common.
Study reported no OR by RECIST criteria, but evidence of
tumor necrosis seen on MRI in 5 patients with questionable PR
was noted.
A phase I study of telomerase-specific replication
competent oncolytic adenovirus (telomelysin) for
various solid tumors [85] (Nemunaitis 2010).
H103 (Adenovirus expressing
HSP70) Advanced solid tumors 27
Study used intratumoral injection of virus in a dose escalation
phase I study. Rare grade III fever and grave IV
thrombocytopenia at high doses was observed. Most AE were
fever, and a local reaction at the injection site, as well as
thrombocytopenia, and depressed leukocyte and lymphocyte
counts. Study reported 48% of patients had at least SD or better,
and 11% had CR or PR.
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Phase 1 study of intravenous administration of the
chimeric adenovirus enadenotucirev in patients
undergoing primary tumor resection [86]
(Garcia-Carbonero 2017).
Enadenotucirev (adenovirus aka
ColoAd1)
Colorectal, NSCLC, Urothelial,
RCC 17
Study used IV infusion for NSCLC, RCC and urothelial cancers,
and intrathehecal injection in colorectal cancer.
Both demonstrated high local CD8+ cell infiltration, with no
significant treatment-related AE.
Phase I study of replication-competent
adenovirus-mediated double suicide gene therapy
for the treatment of locally recurrent prostate
cancer [87] (Freytag 2002).
Five-year follow-up of trial of
replication-competent adenovirus-mediated
suicide gene therapy for treatment of prostate
cancer [88] (Freytag 2007).
Ad5-CD/TKrep Prostate (recurrent) 16
Patients were injected with virus, and two days later received
ganciclovir and 5-fluorocytosine prodrug. Study reported >25%
decreased PSA levels in 44% of patients. A 5-year follow up
showed PSA doubling time was extended in patients who
received the virus treatment indicating that patients had longer
until salvage treatment was needed.
Phase I study of replication-competent
adenovirus-mediated double-suicide gene therapy
in combination with conventional-dose
three-dimensional conformal radiation therapy for
the treatment of newly diagnosed, intermediate- to
high-risk prostate cancer [89] (Freytag 2003).
Ad5-CD/TKrep Prostate 15
Patients had intraprostatic injection of adenovirus with cytosine
deaminase and HSV thymidine kinase genes. 2 days later the
patients received 5-fluorocytosine and valganciclovir prodrug
for up to 4 weeks along with radiation. PSA 1/2 life was
decreased in those with more than 1 week of prodrug therapy.
94% of AE were mild to moderate; severe reactions were similar
to reactions obtained with standard radiation therapy.
Phase I trial of replication-competent
adenovirus-mediated suicide gene therapy
combined with IMRT for prostate cancer [90]
(Freytag 2007).
Ad5-yCD/mutTKSR39rep-ADP Prostate 9
This study used a second generation virus with improved
enzyme activity administered via intraprostatic injection.
Reported AE include 13% with grade 3 lymphopenia; other AE
were grade 1–2. Prostate biopsies at the end of the trial had
fewer positives for residual adenocarcinoma than expected
(22% rather than >40%)
Use of a targeted oncolytic poxvirus, JX-594, in
patients with refractory primary or metastatic liver
cancer: a phase I trial [91] (Park 2008).
Pexa-Vec/JX-594 (pexastimogene
devacirepvec)
Primary or metastatic liver
cancer 14
This was a dose-escalation study of intratumoral injection of
JX-594. Grade 3 hyperbilirubinemia occurred in patients with
the highest dose. All experienced flu-like symptoms, ranging
grade I–III and 4 had short-lived grade I–III dose dependent
thrombocytopenia. Study reported response in the injected as
well as non-injected tumors; 3 PR, 6 with SD and 1 with PD
(and 4 could not be evaluated via imaging for different reasons).
A mechanistic proof-of-concept clinical trial with
JX-594, a targeted multi-mechanistic oncolytic
poxvirus, in patients with metastatic
melanoma [92] (Hwang 2011).
Pexa-Vec/JX-594 (pexastimogene
devacirepvec) Metastatic melanoma 10
Patients were injected intratumorally with 1/10th the dose of
normal JX-594. Biopsies demonstrated evidence of tumor
necrosis, as well as gene expression from JX-594. Clinical
outcomes were not reported (not focus of study). Mild
constitutional symptoms as previously reported
were the only AE.
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Phase 1 study of intratumoral Pexa-Vec (JX-594),
an oncolytic and immunotherapeutic vaccinia
virus, in pediatric cancer patients [93] (Cripe 2015).
Pexa-Vec/JX-594 (pexastimogene
devacirepvec)
neuroblastoma, Ewing
sarcoma, HCC 3
Intratumoral injection of Pexa-Vec in 3 patients. All 3 developed
skin pustules (grade 1) that lasted 3–4 weeks. Study reported
no OR by RECIST criteria; one patient had evidence of tumor
necrosis on imaging.
Phase 1b trial of biweekly intravenous Pexa-Vec
(JX-594), an oncolytic and immunotherapeutic
vaccinia virus in colorectal cancer [94] (Park 2015).
Pexa-Vec/JX-594 (pexastimogene
devacirepvec) Colorectal 15
Study used IV infusion of Pexa-Vec in 15 patients. AE were
grade 1–2, and mostly constitutional symptoms such as fever,
malaise, chills, myalgias. Study reported 67% patients with SD
as seen on imaging.
Vectorized gene therapy of liver tumors:
proof-of-concept of TG4023 (MVA-FCU1) in
combination with flucytosine [95] (Husseini 2017).
TG4023 (MVA-FCU1 modified
vaccinia virus)
Primary or metastatic liver
tumors resistant to other
forms of treatment
16
TG4023 contains the gene for an enzyme to convert flucytosine
into cytotoxic 5-fluorouracil. 16 patients had intratumoral
injection at escalating doses, and then the prodrug (flucytosine)
on day 2. Tumor biopsy demonstrated therapeutic levels of the
active drug were reached. 7 patients had dose limiting toxicity
with non-sustained rise in AST and ALT. Most frequent AE were
constitutional symptoms including anorexia, fever, and fatigue.
Study reported 50% of patients with SD, the other half with PD.
Phase I trial of intravenous oncolytic vaccinia virus
(GL-ONC1) with cisplatin and radiotherapy in
patients with locoregionally advanced head and
neck carcinoma [96] (Mell 2017).
GL-ONC1 (Vaccinia Virus)
Head and Neck Cancer
(locoregionally advances
without metastasis)
19
Study used IV injection of virus along with cisplatin and
radiotherapy. Most AE were grade 1–2 constitutional
symptoms and rash, but 2 patients had grade 3 hypotension,
nausea/vomiting and mucositis. Study reported 5/19 patients
had virus present in the biopsy. At 1 year/2 years: 74.4%/64.1%
with PFS and 84.6%/69.2% OS
First-in-man study of western reserve strain
oncolytic vaccinia virus: safety, systemic spread,
and antitumor activity [97] (Zeh 2015).
vvDD (Poxvirus – western
reserve strain oncolytic vaccinia
virus)
Advanced solid tumors 16
Study used intratumoral injection of virus. Selective viral
replication reported in both injected and non-injected rumors.
Study reported 1 grade 3 events occurred, which was pain in a
breast cancer patient around the time of highest inflammation.
Phase 1 Study of intravenous oncolytic Poxvirus
(vvDD) in patients with advanced solid
cancers [98] (Downs-Canner 2016).
vvDD (Poxvirus – western
reserve strain oncolytic vaccinia
virus)
Advanced colorectal or other
solid cancers 11
Study used IV administration. No dose limiting toxicities
reported, and most AE were grade 1 or 2 constitutional
symptoms. Study reported Th1 cytokines and inflammatory
reaction occurred. A mixed response on some liver metastasis
with improvement of cutaneous melanoma.
Oncolytic measles virus in cutaneous T cell
lymphomas mounts antitumor immune responses
in vivo and targets interferon-resistant tumor
cells [99] (Heinzerling 2005).
MV (Measles Virus,
Edmonston-Zagreb strain) Cutaneous T cell Lymphoma 5
Study used intratumoral injections of live virus with dose
escalation. Endpoint was TBI (Tumor Burden Index: 1 lesion
resolved (CR); 2 showed evidence of regression in local but
non-injected lesions; remaining tumors unchanged. AE
included grade 1 injection site erythema, arthralgias,
itching only
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Phase I trial of systemic administration of
Edmonston strain of measles virus genetically
engineered to express the sodium iodide
symporter in patients with recurrent or refractory
multiple myeloma [100] (Dispenzieri 2017).
MV-NIS (measles virus with
sodium iodide symporter)
Relapsed and refractory
multiple myeloma 29
Study used IV injection; one group with MV-NIS alone, another
with cyclophosphamide prior to MV-NIS treatment. Study
reported grade 3–4 hematologic AEs including decreased blood
counts neutropenia, thrombocytopenia, anemia, and
lymphopenia for both groups. 1 CR reported with some cases of
short lived decreased circulating free light chains (increased
once the body cleared the virus). Iodine was used to identify
infection in myeloma cells.
Phase I trial of intraperitoneal administration of an
oncolytic measles virus strain engineered to
express carcinoembryonic antigen for recurrent
ovarian cancer [101] (Galanis 2010).
MV-CEA (Measles virus,
Edmonston strain)
Taxol and platinum-refractory
recurrent ovarian with normal
CEA levels
21
Study used intraperitoneal injection of the virus with CEA as
measure of viral replication. Study reports best response (per
RECIST) was SD in 14/21 and was dose dependent; 5 patients
had marked decrease of CA-125 levels. Median survival was
12·15 compared to 6 months for historical controls.
Phase I trial of Seneca Valley Virus (NTX-010) in
children with relapsed/refractory solid tumors: a
report of the Children’s Oncology Group [102]
(Burke 2015).
NTX-010 (Seneca Valley Virus)
Pediatric patients wih
neuroblastoma,
rhabdomyosarcoma, rare
tumors with NET features
22
Study designed in 2 parts: part A was dose finding, virus only,
using 3 doses; part B added cyclophosphamide. Study reported
AEs were leukopenia, neutropenia; tumor pain in 1 patient was
the only grade 3 toxicity observed. Nearly all patients (17/18)
had neutralizing antibodies which prohibited virus efficacy.
Phase I clinical study of Seneca Valley Virus
(SVV-001), a replication-competent picornavirus,
in advanced solid tumors with neuroendocrine
features [103] (Rudin 2011).
SVV-001 (Seneca Valley Virus, a
picornavirus)
Advanced solid tumors with
neuroendocrine features 30
Study used IV injection of virus. 1 patient with SCLC was
progression free at 10 months. AEs included flu like symptoms
(fever, fatigue headache) and one grade 3 lymphopenia
A phase I dose-escalation clinical trial of
intraoperative direct intratumoral injection of
HF10 oncolytic virus in non-resectable patients
with advanced pancreatic cancer [104]
(Nakao 2011).
HF-10 Pancreatic cancer 6
Study used 3 intratumoral injections of HF-10. Study reported
PD in 2 patients, SD in 3 patients, and 1 had a PR.
No AE reported.
A Phase I clinical trial of EUS-guided intratumoral
injection of the oncolytic virus, HF10 for
unresectable locally advanced pancreatic
cancer [105] (Hirooka 2018).
HF-10 Pancreatic cancer 10
Study used EUS injection of HF10 for unresectable pancreatic
cancer up to 4 times, every 2 weeks. Co-treatment was erlotinib
and gemcitabine. Study reported AEs: 5 patients with severe
myelosuppression; 2 patients had severe events not due to HF10.
Study outcomes: 2 PD, 4 SD, and 3 PR. PFS 6·3 months, OS 15·5
months. 2 patients achieved CR after downstaging and surgery.
Results of a randomized phase I gene therapy
clinical trial of nononcolytic fowlpox viruses
encoding T cell costimulatory molecules [106]
(Kaufman 2014).
rF-B7.1 and rF-TRICOM
(recombinant fowlpox virus with
either B7.1 or three genes: B7.1,
ICAM-1, and LFA-3)
Melanoma and colon cancer 12
Study used intratumoral injection of one of the two viruses and
at varying doses, every 4 weeks. AE were minimal, including
injection site pain and pyrexia (in only 4 patients). Study
reported no objective clinical responses but safety was
established, and some T cell activity specific to the tumors was
seen Stable disease noted for 3 patients which included both
colon cancer cases.
AE, adverse event; CR, complete response; GI, gastrointestinal; ICH, intracerebral hemorrhage; LFT, liver function test; MM, multiple myeloma; MR, marginal response; MTD, maximum
tolerated dose; NARA, neutralizing antivirus antibody; OR, overall response; ORR, objective response rate; OS, overall survival; PD, progressive disease; PFS, progression free survival; PR,
partial response; RECIST, response evaluation criteria in solid tumors; SCLC, small cell lung cancer SD, stable disease.
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11. Pexa-Vec
Pexa-Vec/JX-594, or pexastimogene devacirepvec, is an oncolytic pox virus that has been studied
across a variety of malignancies, including melanoma, colorectal cancer, and liver metastases.
This vaccinia virus was altered for oncolytic activity by deactivation of its thymidine kinase, with the
addition of granulocyte–macrophage colony-stimulating factor (GM-CSF). The GM-CSF is added to
increase oncolysis and induce adaptive immune response to the tumor cells [107]. A majority of the
studies focused on liver cancers, either HCC or metastases to liver. In one study, 14 patients received
intratumoral injections of the virus. Grade III hyperbilirubinemia was observed with the highest dosed
group, and 4 patients experienced transient thrombocytopenia, as high as grade 3. Under RECIST
criteria, 3 patients had a partial response (PR) and 6 had stable disease (SD). Interestingly, a response
could be seen not only in the tumors that had been injected, but also in the satellite lesions [108].
Pexa-vec has also been studied using IV administration. In a study of 15 patients with colorectal
cancer, IV infusion of Pexa-vec resulted in SD in 67% of patients [94]. Pexa-vec showed promise in
phase II clinical trials (see Table 3), but the Phase III trial that combined Pexa-vec with sorafenib in
patients with metastatic HCC (Clinical Trial: NCT02562755) was terminated in august 2019 due to lack
of effectiveness.
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Trial Name Virus Cancer n Outcomes
Randomized phase IIB evaluation of weekly
paclitaxel versus weekly paclitaxel with
oncolytic reovirus (Reolysin®) in recurrent
ovarian, tubal, or peritoneal cancer [109]
(Cohn 2017).
Reolysin Ovarian, tubal or peritoneal cancer 108 Study reported Reolysin did not improve outcomesenough to induce further study.
Phase II trial of intravenous administration of
Reolysin(®) (Reovirus Serotype-3-dearing
Strain) in patients with metastatic
melanoma [110] (Galanis 2012).
Reolysin Melanoma 21
Viral replication confirmed in biopsies; 1 patient had
75–90% tumor necrosis, which provided evidence for
treatment effect.
A phase II study of REOLYSIN® (pelareorep)
in combination with carboplatin and paclitaxel
for patients with advanced malignant
melanoma [111] (Mahalingam 2017).
Reolysin Melanoma 14
Study reported 3 partial responses: 1% ORR; PFS 5·2
months; OS 10·9 months. 1 year OS was 43%. Disease
control rate 85%.
Randomized phase 2 trial of the oncolytic virus
Pelareorep (Reolysin) in upfront treatment of
metastatic pancreatic adenocarcinoma [112]
(Noonan 2016).
Reolysin Metastatic pancreaticadenocarcinoma 73
Study reported that addition of Reolysin to
paclitaxel+carboplatin, did not improve PFS, but was
well-tolerated. Presence of KRAS mutation also did not
affect outcome.
A Phase II study of Pelareorep (REOLYSIN®)
in combination with gemcitabine for patients
with advanced pancreatic
adenocarcinoma [113] (Mahalingam 2018).
Reolysin Pancreatic adenocarcinoma 34
Study reported OS (10·2 vs. 6·8 months) as well as 1-
and 2-year survival (45% and 22%, respectively) was
increased compared to historical controls that used
single agent gemcitabine (20–22%, 2·5%).
A randomized phase II study of weekly
paclitaxel with or without pelareorep in
patients with metastatic breast cancer: final
analysis of Canadian Cancer Trials Group
IND.213 [114] (Bernstein 2018).
Reolysin Metastatic breast cancer 74
There was no statistical difference in RR or PFS but there
was increased OS: 17·4 months vs. 10·4 months with
paclitaxel alone.
Prospective randomized phase 2 trial of
intensity modulated radiation therapy with or
without oncolytic adenovirus-mediated
cytotoxic gene therapy in intermediate-risk
prostate cancer [115] (Freytag 2014).
Ad5-yCD/mutTKSR39rep-ADP
adenovirus Prostate 44
Combined intensity modulated radiation therapy
(IMRT) with adenovirus. Significant decrease in the
number of positive biopsies at 2 years: IMRT 58%;
IMRT+virotherapy 33% (P = 0.13).
Intraprostatic distribution and long-term
follow-up after AdV-tk immunotherapy as
neoadjuvant to surgery in patients with
prostate cancer [116] (Rojas-Martinez, 2013).
AdV-tk (aka aglatimagene
besadenovec or ProstAtak Prostate 10
Injected AdV-tk with valcyclovir or ganciclovir in 9
patients scheduled for prostatectomy. 6 of these patients
had high risk features. At 10 years did not have signs of
recurrence/metastasis. Historic controls with high risk
features typically have 15% PSA failure with 34% of
those have metastasis [117] (Pound 1999)
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Phase II multicenter study of gene-mediated
cytotoxic immunotherapy as adjuvant to
surgical resection for newly diagnosed
malignant glioma [118] (Wheeler 2016).
AdV-tk (aka aglatimagene
besadenovec or ProstAtak Glioma 48
Patients with malignant gliomas were injected AdV-tk
during surgery. They then received valcyclovir along
with standard therapy of radiation and temozolomide.
Overall survival was extended for those who received
viral therapy (especially in the group in which total
gross resection was achieved at the initial surgery).
A controlled trial of intratumoral ONYX-015, a
selectively-replicating adenovirus, in
combination with cisplatin and 5-fluorouracil
in patients with recurrent head and neck
cancer [119] (Khuri 2000).
ONYX-15 Recurrent squamous cell head andneck cancer 37
Patients were given cisplatin/5 FU along with
intratumoral injection of ONYX-015. Study reported
27% CR and 36% PR. There were flu-like symptoms and
injection site pain most commonly, and rare grade 3–4
mucositis.
Selective replication and oncolysis in p53
mutant tumors with ONYX-015, an E1B-55kD
gene-deleted adenovirus, in patients with
advanced head and neck cancer: a phase II
trial [120] (Nemunaitis 2000).
ONYX-15 Recurrent head and neck cancer 37
Intratumoral injection of virus led to marked tumor
regression (as defined as >50% of lesion) in 21% of
patients. Biopsy of surrounding normal tissues were
negative for viral infection.
Hepatic arterial infusion of a
replication-selective oncolytic adenovirus
(dl1520): phase II viral, immunologic, and
clinical endpoints [37] (Reid 2002).
Onyx-015 (Adenovirus
dl1520)
Gastrointestinal cancer with liver
metastasis 27
Study used hepatic artery infusion of the virus in
combination with traditional chemotherapy (5-FU and
leucovorin). Study reported biochemical response with
virotherapy (increase TNF, IFN-gamma, IL-6 and IL-10)
in some tumors resistant to chemotherapy alone. Some
grade 3–4 adverse events were seen with
hyperbilirubinemia.
Effects of Onyx-015 among metastatic
colorectal cancer patients that have failed prior
treatment with 5-FU/leucovorin [121]
(Reid 2005).
Onyx-015 (Adenovirus
dl1520)
Colorectal cancer with
metastasis to liver 24
Study used hepatic artery infusion of virus in subjects
that failed 5-FU/leucovorin. Study reported mixed
results: some evidence of tumor necrosis and regression;
many patients removed early due to CT-demonstrated
enlargement of tumors. However, CT information may
reflect inflammation in response to tumor infection with
virus prior to regression; PET rather than CT use
suggested in the future.
An open label, single-arm, phase II multicenter
study of the safety and efficacy of CG0070
oncolytic vector regimen in patients with
BCG-unresponsive non-muscle-invasive
bladder cancer: Interim results [122]
(Packiam 2017).
CG0070 (GM-CSF
expressing adenovirus)
Non-muscle invasive bladder
cancer (NMIBC), 45
Study used intravesical CG0070 for those resistant to
bacillus Calmette–Guerin (BCG). Study reported a 47%
CR at 6 months.
Int. J. Mol. Sci. 2020, 21, 7505 20 of 36
Table 3. Cont.
Trial Name Virus Cancer n Outcomes
Randomized dose-finding clinical trial of
oncolytic immunotherapeutic vaccinia JX-594
in liver cancer [108] (Heo 2013),
Pexa-Vec (JX-594 vaccinia
virus) HCC 22
mRECIST and Choi tumor response rates were
equivalent for the low and high dose treatment groups.
Median survival was greater in the high dose group
(14·1 months vs. 6·7 months).
Phase II trial of Pexa-Vec (pexastimogene
devacirepvec; JX-594), an oncolytic and
immunotherapeutic vaccinia virus, followed
by sorafenib in patients with advanced
hepatocellular carcinoma (HCC) [123]
(Heo 2013).
Pexa-Vec (JX-594 vaccinia
virus) HCC 25
Study used Pexa-Vec IV for Day 1 followed by
intratumoral injections on Days 8 and 22; sorafenib was
administered on Day 25. Per mRECIST criteria, 62% had
disease control after Pexa-vec treatment, and 59% after
use of sorafenib.
Phase II clinical trial of a
granulocyte-macrophage colony-stimulating
factor-encoding, second-generation oncolytic
herpesvirus in patients with unresectable
metastatic melanoma [35] (Senzer 2009).
OncoVEXGM–CSF (Herpes
Virus
JS1/34·5-/47-/GM-CSF)
Melanoma 50
Study used intratumoral injection of the virus. Study
reported a 26% response rate using the RECIST criteria
which included uninjected tumors
(and even visceral tumors).
Phase II clinical study of intratumoral H101, an
E1B deleted adenovirus, in combination with
chemotherapy in patients with cancer [124]
(Xu 2003).
H101 (E1B deleted
adenovirus) Malignant tumors 50
Study used intratumoral injection 5 days/week for 3
weeks along with standard chemotherapy. Response
rate was 28% vs 13% in control group. Grade 4
hematologic AE in 4 patients.
Phase I Trial of an ICAM-1-Targeted
Immunotherapeutic-Coxsackievirus A21
(CVA21) as an Oncolytic Agent Against Non
Muscle-Invasive Bladder Cancer [125]
(Annels 2019)
Coxsackievirus A21
(CVA21)
Non-muscle invasive bladder
cancer 15
Nine patients received intravesicular injection of virus; 6
patients received viral injection and subtherapeutic
mitotycin C before resection. 1 CR (by histology) No
serious AE reported.
A Study of Intratumoral CAVATAK™ in
Patients with Stage IIIc and Stage IV Malignant
Melanoma (VLA-007 CALM) (CALM) [126]
(NCT01227551)
Coxsackievirus A21
(CVA21)
Stage IIIc and Stage IV Malignant
Melanoma 57
Intratumoral injection of virus. Reported 38·6%
immune-related Progression-Free Survival at 6 months,
21% durable response rate (CR+PR). 19% experience
severe AE.
5-FU, fluorouracil; AE, adverse response; BCG, bacillus Calmette–Guerin; CT, computerized tomography; IL-6/IL10, interleukin 6/interleukin 10; IMRT, intensity modulated radiation
therapy; IFN, interferon; mRECIST, modified RECST; ORR, objective response rateOS, overall survival; PET, positron emission tomography; PFS, progression free survival; RECIST,
response evaluation criteria in solid tumors; RR, response rate; TNF, tumor necrosis factor.
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12. Ad5/3 delta 24 (CRAd)
Ad5/3 delta 24 is an oncolytic adenovirus being studied for application across a number of
malignancies, and prominently with gynecologic cancers. The virus gains entry into cells by binding
to the Ad3 receptor, which has increased expression on tumor cells. Delta-24 signifies a 24 base pair
deletion in the E1a gene, leading to preferential replication in cells with defective retinoblastoma (Rb)
expression, a common occurrence in tumor cells. Twenty-one patients with gynecologic malignancies
received intraperitoneal injection of the OV. The treatment was well tolerated with only grade 1–2
adverse events (AE) of fatigue, malaise, and abdominal pain. The study reported that 67% achieved
SD, with the remainder progressing after 1 month [72].
Ad5/3 delta 24 has been further manipulated with the addition GM-CSF gene to stimulate immune
activity, with strains such as CGTG-102 and CGTG-602. In a study of CGTG-102, 60 patients with
advanced solid tumors received either single of multiple dose intratumoral injections of the OV.
Stable disease or better was reached in 51% of patients who received serial injections (vs. 41% in single
injection). AE were minimal and limited to grade 1–2 flu-like symptoms.
13. Seneca Valley Virus
Seneca Valley Virus (SVV) is a more recent addition into OV group therapy. Its application
focuses on tumors with neuroendocrine features, and has also proven safe in treatment of pediatric
tumors [102]. In a study of 22 pediatric patients with neuroblastoma, rhabdomyosarcoma, and rare
tumors with NET features, NTX-010, a SVV strain, was studied alone and in combination with
cyclophosphamide. Adverse events included leukopenia, neutropenia, and tumor pain, but only 1
grade 3 toxicity (tumor pain) was reported. In another trial of SVV, SVV-001, 30 patients with advanced
solid tumors with neuroendocrine features received IV injections of the OV. One patient with SCLC
was progression free for 10 months [103]. This is a promising finding that warrants future study with
neuroendocrine malignancies. However, a phase 2 study evaluating the efficacy of SVV in extensive
stage small cell carcinoma was unfortunately negative. Non-progressive patients post 4 cycles of
platinum doublet were randomized 1:1 to receive single IV infusion of SVV vs placebo. This trial was
terminated due to futility as no improvement in median PFS was seen at interim analysis [127].
Recently a novel biomarker called tumor endothelial marker 8 (TEM 8) has been confirmed to act
as a receptor for SVV, facilitating in viral entry in tumor cells. TEM 8 pre-screening can potentially
form an important strategy to select patients for SVV therapeutic clinical trials [128].
14. Polio Virus
PVSRIPO is an oncolytic polio virus that has demonstrated promising results in the treatment of
glioblastoma. It is engineered to target CD155/Necl5, the onco-fetal adhesion protein found in many
solid tumors. In a study of 61 patients, the virus was injected intratumorally (Desjardins 2018) [69].
AE were minimal, with grade 4 intracranial hemorrhage occurring at only the highest injection dose.
Survival is higher as compared to historical controls. Studies are underway to determine the safety
of the therapy in pediatric glioma (NCT03043391) as well as invasive breast cancer (NCT03564782).
It is also being studied in combination with immunotherapy for melanoma, including nivolumab
(NCT04125719) and Atezolizumab (NCT03973879)
15. MV-NIS
MV-NIS is a unique oncolytic virus, composed of an Edmonston strain of measles virus which
has been altered to express a sodium iodide transporter. Measles virus can target tumor cells through
the CD46 antigen. Additionally, infection of tumor cells by the virus can be monitored through
administration of Iodine-123 via SPECT imaging.
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MV-NIS has been studied in the treatment of myeloma, and has exhibited promising results.
In a study of 29 patients 1 CR was reported (Dispenzieri 2017) [100]. There were also some cases of
decreased circulating free light chains, but they did increase once the patient cleared the virus.
16. Phase II Trials
Those viruses that were safe and had early clinical evidence of success progressed to Phase II
studies. Phase II investigations seek to demonstrate clinical efficacy. Thirteen viruses across 24 trials
were available for review. The review of Phase II data also included 6 Phase I/II trials. Again, because
of limitation of space, we will discuss a few OVs used across a variety of cancers. A complete table of
Phase I/II and Phase II trials in our review can be found in Tables 3 and 4, respectively.
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Table 4. Summary of oncolytic virus use in Phase I/II studies.
Trial Name Virus Cancer n Administration, Adverse Events, Study Conclusions
Phase I/II trial of carboplatin and paclitaxel
chemotherapy in combination with
intravenous oncolytic reovirus in patients with
advanced malignancies [129]
(Karapanagiotou 2012).
RT3D (Reovirus Type 3 Dearing) Advanced head and neck cancer 31
Study used IV infusion of RT3D with
carboplatin/paclitaxel. Study reported treatment was
well tolerated, no MTD, and toxicities were largely
grade I/II. Outcomes reported by RECIST were 1 CR
(3·8%) and 6 PR (23·1%).
Oncolytic H-1 parvovirus shows safety and
signs of immunogenic activity in a first phase
I/IIa glioblastoma trial [130] (Geletneky 2017).
Parvovirus Glioblastoma 18
Study used IV and intratumoral injection into cavity
created from resection. Study reported: no MTD was
reached; T cell infiltration and activation of
macrophages and microglia were detected in the
infected tumors (Evidence that it is stimulating the
immune system) Median survival increased compared
to recent meta-analyses.
Phase I/II study of oncolytic HSV GM-CSF in
combination with radiotherapy and cisplatin in
untreated stage III/IV squamous cell cancer of
the head and neck [131] (Harrington 2010).
HSV GM-CSF Stage III/IV squamous cellcancer of head and neck 17
Study used intratumoral injection every 21 days with
radiation and cisplatin; neck dissection 6–10 weeks later.
Study reported a median follow up of 29 months with
76·5% relapse free rate, 100% locoregional control
(60–70% in historical controls).
Phase I/II study of oncolytic herpes simplex
virus NV1020 in patients with extensively
pretreated refractory colorectal cancer
metastatic to the liver [132]
(Geevarghese 2010).
NV1020 (Herpes Virus) Colorectal liver metastases I 13II 19
Study used hepatic arterial injections with virus then
standard chemotherapy in patients with relapse. Study
documents 50% SD with a median survival longer than
historical controls.
Phase I–II trial of ONYX-015 in combination
with MAP chemotherapy in patients with
advanced sarcomas [133] (Galanis 2005).
Onyx-015 (Adenovirus dl1520) Advanced sarcomas 6
Study used intratumoral injection of the virus in
combination with MAP applied to metastases in the
liver and chest wall. No significant toxicities identified.
Study outcomes include:1 patient with PR that lasted 11
months; tumor had p53 mutation and
MDM-2 amplification
Phase I/II trial of intravenous NDV-HUJ
oncolytic virus in recurrent glioblastoma
multiforme [134] (Freeman 2006).
NDV-HUJ (HUJ strain of
Newcastle disease virus) glioblastoma multiforem 14
Study used IV injection of virus. Study reported AEs
grade I/II constitutional symptoms. 1 person with CR.
CR, complete response; MAP, mitomycin-C+ doxorubicin+cisplatin; MTD, maximum tolerated dose; OS, overall survival; PR, partial response; RECIST, response evaluation criteria in
solid tumors; SD, stable disease.
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17. Reolysin
Reolysin (Pelareorep) is a strain of the reovirus type 3D that has been investigated in a variety of
cancers, including ovarian, breast, melanoma, pancreatic, glioma, and multiple myeloma. Ten Phase I
trials are in summarized in Table 2. This OV has provided particularly promising evidence, and use in
Phase II trials have increased OS in multiple cancers. In one study of 74 patients with metastatic breast
cancer, OS increased as compared to paclitaxel monotherapy (17·4 months vs. 10·4 months) [114]. In a
smaller study of 14 patients with melanoma, the addition of Reolysin to paclitaxel and carboplatin saw
a 21% ORR (3 patients) [111]. Reolysin in combination with gemcitabine was superior to gemcitabine
monotherapy in a study of 34 patients with pancreatic cancer [113]; OS and 1- and 2-year survival
was increased. Outcomes were similar to those undergoing FOLFIRINOX therapy, but the side effect
profile was better tolerated with Reolysin+gemcitabine. The same success has yet to be demonstrated
ovarian cancer. In a trial with 108 patients with ovarian, tubal or peritoneal cancer receiving paclitaxel,
adding Reolysin did not improve outcomes [109].
18. ProstAtak
ProstAtak/aglatimagene besadenovec/Adv-tk is an adenovirus which has been modified to express
HSV thymidine kinase. After infection of tumor cells with the virus, valcyclovir or ganciclovir is
administered that subsequently induces cell death. As the name may suggest, this OV was engineered
for application in prostate cancer, but has also been tested in other cancers including a Phase II trial
with gliomas. In one study of 48 patients with malignant gliomas, AdV-tk was injected into the tumor
cavity following resection, and subsequently received valcyclovir. Overall survival was extended
in the treatment group, particularly in those patients that achieved total gross resection at time of
surgery [118]. In studies that involve prostate cancer, one example included a study of 10 patients
who received intraprostatic injection of Adv-tk as neoadjuvant therapy to surgery. PSA levels were
monitored as a marker of tumor suppression. Eight of nine patients continued to have reduced PSA
levels 10 years following injection.
19. ONYX-015
ONYX-015 (previously known as Ad2/5 dl1520) is an oncolytic adenovirus which was engineered
to target p53-deficient cells. This adenovirus is deficient in a portion of the E1B gene that produces
a 55 kDa protein. This protein typically binds to p53 to prevent apoptosis; in p53-deficient cells,
the virus can replicate and lyse cancer cells. Phase II trials involved those for head and neck cancer as
well as liver metastases of gastrointestinal cancers. Intratumoral injection of head and neck cancers
demonstrated marked (> 50%) tumor regression in 14% of patients [135] It has also been studied
in combination with 5-FU/cisplatin, for which there was 27% CR and 36% PR [119]. Hepatic artery
infusion of the virus was used in 2 studies, either in combination with 5-FU/Leucovorin, or as a single
agent in patients who had previously failed 5-FU/Leucovorin therapy. While there was evidence of
biochemical response, increased interleukins and other immune stimulatory molecules, no clinical
response was seen [37]. In the ONYX-15 single agent study [121] many patients were removed from
the study due to concern about cancer progression seen on CT imaging. It was suggested alternate
imaging, such as PET should be utilized in the future as this technology suggested that the increase in
tumor size may have been inflammatory response from viral induced infection and inflammation.
20. Cavatak
Cavatak, otherwise known as CVA21, is a coxsackievirus which targets ICAM-1 to gain entry
into tumor cells. Currently there is data available for studies investigating the virus’ use in
advanced melanoma and non-muscle invasive bladder cancer. In a phase I study of 15 patients
with non-muscle-invasive bladder cancer, patients received intravesicular injection of the virus.
No serious AE occurred, and 1 CR was reported. A phase II study examined 57 patients with
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intratumoral injection CVA21 with advanced melanoma. There was a 21% durable response rate
(CR+PR).
There are a number of current trials investigating Cavatak, predominantly in combination with
immunotherapy. Its safety for use in NSCLC, melanoma, bladder cancer, and prostate cancer is being
studied in the STORM trial (NCT02043665), with an additional arm in the bladder cancer and NSCLC
groups to be used in combination with pembrolizumab. The CAPRA study (NCT02565992) is also
combining Cavatak with pembrolizumab in metastatic melanoma. The MITCI trial (NCT02307149) is
combining intratumoral Cavatak with Ipilimumab in metastatic melanoma.
21. Phase 3 Trials
In our systematic review, available Phase III data were limited to 2 trials of talimogene
herparepvec (Table 5).
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Table 5. Summary of oncolytic virus use in Phase III clinical trials.
Trial Name Virus Cancer n Central Questions and/or Outcomes
A Study of Talimogene Laherparepvec in stage
IIIc and stage IV malignant melanoma [136]
(Andtbacka 2015).
Talimogene Laherparepvec Stage IIB-IV melanoma 295
T-VEC was compared to subcutaneous GM-CSF.
Higher DRR at 6 months and greater median OS with
T-VEC particularly in untreated advanced melanoma.
Lesions that were not directly injected showed response.
OS was not improved.
Phase IIIb safety results from an
expanded-access protocol of talimogene
laherparepvec for patients with unresected,
stage IIIB-IVM1c melanoma [137]
(Chesney 2018).
Talimogene Laherparepvec Melanoma 41
Safety profile was consistent with previous trials. As
compared to OPTIM trial above, this trial also included
ECOG of 2 (OPTIM was 0, 1 only). Efficacy was not
assessed, as the primary outcome was to provide
expand access to T-VEC until FDA approval.
AE, adverse response; DRR, durable response rate; OS, overall survival.
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22. Talimogene Herparepvec
Talimogene herparepvec (T-vec) is currently the only FDA approved OV [2] available in the US.
T-vec is an HSV-1 virus, which expresses human GM-CSFT-vec, that can only replicate in cancer cells.
This happens because of a dysfunctional PKR pathway in cancer cells. In normal cells, viral infection
causes PKR activation, which in turn, leads to an inhibition of protein synthesis within the cell and
ultimately decreased viral replication. In contrast, with a dysfunction RKP system in cancer cells,
viral replication proceeds unhindered [138]. However, in cancerous cells allow replication by the virus.
T-vec is indicated for unresected advance stage melanoma, administered via intratumoral
injection [2]. Phase 3 trials demonstrated mixed results [36,137]. The safety profile was consistent
with previous trials, with flu-like symptoms and injection site pain reported; 7% of patients had
grade 3 or higher AE including nausea, vomiting, fever and abdominal pain. In the OPTiM Phase
III trial [36] tumors that were not injected also demonstrated regression, which indicated possible
systemic efficacy. Despite this, OS was not increased. Other studies compared T-vec to simple GM-CSF
injection; T-vec produced a higher DRR (durable response rate) and increased OS than did GM-CSF
alone [136].
T-vec has also been studied in combination with immunotherapy in initial phase I studies [28,139].
T-vec was injected into lesions with systemic ipilimumab therapy. Combining these two agents is
more effective that either treatment alone. In another investigation, combination with pembrolizumab
demonstrated increased ORR as compared pembrolizumab alone [28].
There is a Phase III trial underway examining combination therapy of systemic pembrolizumab
with intratumoral injection of T-vec (NCT02263508).
23. Limitations of OVs
Despite the exciting evidence presented in the previously mentioned trials, OV therapy has
limitations. One challenge is delivering the virus to the targeted lesions. Intratumoral injection is
limited to accessible tumors such as melanomas, or targeted hepatic artery injection for hepatic lesions.
While IV administration would be ideal, it can lead to sequestration of virus in the liver, limiting whole
body distribution [140] as well as development of neutralizing antibodies.
Neutralizing antibodies are one of the greatest barriers to OV efficacy. Viruses selected for
oncolytic virotherapy are those that can infect human cells, which carries both benefits and drawbacks
for treatment. Many humans have been previously exposed to or vaccinated against some of the
naturally occurring viruses used in OV therapy, and subsequently possess neutralizing antibodies
to the virus. Nearly 90% of humans have antibodies against reovirus [141]. The measles virus is in
development as an OV, and its success is hindered by the patient’s circulating antibodies [142].
24. Conclusions
The success of immune checkpoint inhibitors has propelled the field of oncology towards exploring
other immunotherapeutic mechanisms to abrogate cancer growth. Oncolytic viruses are one such
promising avenue with the potential to advance oncology therapeutics. While there has been only one
FDA approved anticancer agent to date, a multitude of the oncolytic virus in various stages of clinical
development makes for a promising story yet to unfold. The biggest advantage we have in harnessing
oncolytic viral therapy lies in our capability to bioengineer these nanomicrobes. With improved
understanding of molecular pathophysiology, we have the potential to manipulate oncolytic viruses to
match evolving cancer challenges.
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